NEWS
NEWS
NEWS
Q&A WITH JEFF ARONIN, CHAIRMAN AND CEO OF PARAGON BIOSCIENCES
May 24, 2019
Jeff Aronin, Chairman and CEO of Paragon Biosciences, has spent more than two decades in one of the most challenging areas of the biosciences sector. He and his teams have worked to find treatments for patients with especially complex and often rare diseases – diseases sometimes affecting less than 200,000 Americans – who do not attract the research interest of companies pursuing “blockbuster drugs.”
Paragon Biosciences creates leverage for Aronin’s quest because Paragon is a life science innovator that invests in, builds, and advises a portfolio of bioscience companies which develop potentially more effective treatments for severe diseases.
Access the entire interview here:
Q&A WITH JEFF ARONIN, CHAIRMAN AND CEO OF PARAGON BIOSCIENCES
May 24, 2019
Jeff Aronin, Chairman and CEO of Paragon Biosciences, has spent more than two decades in one of the most challenging areas of the biosciences sector. He and his teams have worked to find treatments for patients with especially complex and often rare diseases – diseases sometimes affecting less than 200,000 Americans – who do not attract the research interest of companies pursuing “blockbuster drugs.”
Paragon Biosciences creates leverage for Aronin’s quest because Paragon is a life science innovator that invests in, builds, and advises a portfolio of bioscience companies which develop potentially more effective treatments for severe diseases.
Access the entire interview here:
Q&A WITH JEFF ARONIN, CHAIRMAN AND CEO OF PARAGON BIOSCIENCES
May 24, 2019
Jeff Aronin, Chairman and CEO of Paragon Biosciences, has spent more than two decades in one of the most challenging areas of the biosciences sector. He and his teams have worked to find treatments for patients with especially complex and often rare diseases – diseases sometimes affecting less than 200,000 Americans – who do not attract the research interest of companies pursuing “blockbuster drugs.”
Paragon Biosciences creates leverage for Aronin’s quest because Paragon is a life science innovator that invests in, builds, and advises a portfolio of bioscience companies which develop potentially more effective treatments for severe diseases.
Access the entire interview here:
